Bluejay Diagnostics Inc.
BJDX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BJDX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BJDX
Bluejay Diagnostics Inc. (BJDX) is a clinical-stage medical diagnostics company developing rapid tests using whole blood on its Symphony platform for critical care settings, with a primary focus on sepsis.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Bluejay Diagnostics Inc..
Bluejay Diagnostics Inc. (BJDX) is a clinical-stage medical diagnostics company developing rapid tests using whole blood on its Symphony platform for critical care settings, with a primary focus on sepsis.
- Clinical-stage company developing the Symphony platform for rapid whole-blood protein detection tests, initially targeting sepsis [sec_mda · as of 2026-03-06].
- Cash and equivalents of $9.6M as of June 30, 2026, with an accumulated deficit of $45.8M [sec_mda · as of 2026-08-12].
- Net loss of $2.3M for the six months ended June 30, 2026 [latest reported financials as of 2026-06-30].
- Plans to begin testing SYMON-II clinical trial samples by end of 2026, aiming for a 510(k) submission to the FDA in 2027 [sec_mda · as of 2026-05-07].
- Company expects to need at least $20M in additional capital through the end of fiscal 2027 to fund operations and clinical trials [sec_mda · as of 2026-05-07].
What works
- The Symphony platform is protected by a combination of Bluejay's IP and exclusively licensed, patented technology, providing a potential competitive moat if cleared by the FDA [sec_mda · as of 2026-05-07].
- The company raised $7.7M in net cash from financing activities in the first half of 2026, including a $7.6M private placement in June 2026, extending its cash runway [sec_mda · as of 2026-08-12].
- Bluejay has no debt on its balance sheet as of June 30, 2026, with total debt of $0.0M [latest reported financials as of 2026-06-30].
What to weigh
- The company has incurred net losses since inception and negative cash flows from operations, with an accumulated deficit of $45.8M as of June 30, 2026 [sec_mda · as of 2026-08-12].
- Bluejay expects to need at least $20M in additional capital through fiscal 2027, and there is substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-08-12].
- The market price of Bluejay's common stock has fallen by more than 99.9% since its November 2021 IPO, and further dilution is likely if additional funding is raised [sec · filed 2026-06-17].
- The company's clinical trial and FDA submission timeline has been delayed due to cash constraints; the current plan targets a 510(k) submission in 2027, but failure to secure financing could force abandonment of activities [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Bluejay is a clinical-stage medical diagnostics company developing rapid tests using whole blood on its Symphony platform.
“We are a clinical-stage medical diagnostics company developing rapid tests using whole blood on our Symphony platform ("Symphony") to improve patient outcomes in critical care settings, with a focus on sepsis.”
SEC MD&A · March 6, 2026
Cash and equivalents were $9,598,916 as of June 30, 2026.
“The Company had cash and cash equivalents of $9,598,916 and current liabilities of $2,116,641 on its balance sheet as of June 30, 2026.”
SEC MD&A · August 12, 2026
The company expects to need at least $20 million of capital through the end of fiscal 2027.
“the Company expects to need to raise at least $20 million of capital between the date of this filing and the end of the 2027 fiscal year”
SEC MD&A · May 7, 2026
The company's stock price has fallen by more than 99.9% since its November 2021 IPO.
“Since the initial public offering of our common stock in November 2021, the market price of our common stock has fallen by more than 99.9%”
SEC filings · June 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to recurring losses and negative cash flows [sec_mda · as of 2026-08-12].
- Need for substantial additional capital — Company expects to need at least $20M through fiscal 2027; failure to raise funds could delay or halt operations [sec_mda · as of 2026-05-07].
- Clinical and regulatory delays — Cash constraints have slowed clinical trial work; 510(k) submission targeted for 2027 but may be further delayed [sec_mda · as of 2026-05-07].
- Extreme stock price decline — Stock price down >99.9% since IPO; future financings may cause further dilution and price declines [sec · filed 2026-06-17].
What to watch
- Ability to raise at least $20M in additional capital through fiscal 2027 to fund operations and clinical trials [sec_mda · as of 2026-05-07].
- Initiation of testing of SYMON-II clinical trial samples by end of 2026 [sec_mda · as of 2026-05-07].
- Progress toward a 510(k) submission to the FDA in 2027 [sec_mda · as of 2026-05-07].
- Any further delays or changes to the regulatory submission timeline due to cash constraints [sec_mda · as of 2026-08-12].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Bluejay Diagnostics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bluejay Diagnostics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
19.3 months
D/E 0.23 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
6 buys · 1 sell (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 28,726 | $53K |
| geode capital management, llc | 28,127 | $52K |
Short Interest
as of May 20, 2026- % of float
- 2.2%
- Days to cover
- 1.4
- Shares short
- 21,481
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BJDX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bluejay Diagnostics Inc.?
Bluejay Diagnostics Inc. (BJDX) is a clinical-stage medical diagnostics company developing rapid tests using whole blood on its Symphony platform for critical care settings, with a primary focus on sepsis.
Who is the CEO of Bluejay Diagnostics Inc.?
Mr. Indranil Dey is the chief executive officer of Bluejay Diagnostics Inc. (BJDX).
Where is Bluejay Diagnostics Inc. headquartered?
Bluejay Diagnostics Inc. (BJDX) is headquartered in Acton, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.